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1. INTRODUCTION role for polyamines in tumor growth and 
metastasis. 
Investigations into the role of polyamines in 
cellular proliferation have been greatly facilitated 
by the availability in recent years of specific in- 
hibitors of polyamine biosynthetic enzymes [ 1,2]. 
Difluoromethyl ornithine (DFMO) is a specific ir- 
reversible inhibitor of ornithine decarboxylase [3] 
and causes rapid depletion of intracellular 
putrescine and spermidine in a number of cells 
grown in culture [4-61. Inhibition of polyamine 
biosynthesis by DFMO results in inhibition of 
tumor growth in a number of transplanted and 
chemically induced animal tumors [7,8]. Although 
these experimental observations are indicative of 
an essential role for polyamines during tumor cell 
proliferation, there is no evidence available for 
their role in tumor metastases. The ability of 
primary tumors to metastasize is a major obstacle 
to curing human cancers. In the present study we 
have examined the effect of DFMO on the growth 
and pulmonary metastasis of Lewis lung (3LL) 
tumor in mice. The Lewis lung tumor of C57 BL 
mice provides an excellent experimental model for 
studying tumor metastases. The primary tumor 
grows rapidly and metastasizes to lungs in 
-3 weeks after tumor transplantation; these 
pulmonary foci can easily be counted. These 
results indicate that inhibition of polyamine 
biosynthesis by DFMO results in a 40-50% inhibi- 
tion of growth of the primary tumor and -80% in- 
hibition of pulmonary metastasis. Further, the ef- 
fects of DFMO could easily be reversed by 
simultaneous administration of putrescine to the 
animals along with DFMO, suggesting an essential 
2. MATERIALS AND METHODS 
2.1. Animals 
C57 BL/6J mice (18-20 g) from Charles River 
were used for the transplantation of the tumor. 
The animals were housed in stainless steel cages 
with free access to food and water. 
2.2. Tumor 
Lewis lung carcinoma (3LL) was kindly supplied 
by Mason Research Institute. The tumor was pro- 
pagated and maintained in vivo by serial transfers 
of dissociated tumor cells in C57 BL/6J mice. 
Rapidly dividing 2-week-old tumors were excised 
from the animals and trypsinised. The resulting cell 
suspension was passed through sterile gauze. The 
viability of the tumor cells in the supernatant was 
determined by Trypan blue dye exclusion method. 
Tumors were induced in mice by subcutaneous in- 
jection of 1 x IO6 viable cells at the interscapular 
region. Tumors started to appear within a week. 
Mice bearing tumors were killed on the 18th day, 
the primary subcutaneous tumor was excised, and 
a portion of the tissue frozen at - 70°C for 
polyamine analysis. The lungs were examined for 
metastases by injecting diluted India ink into the 
trachea before fixation of the whole lung [9]. 
Metastases appeared as white nodules against 
black normal lung. 
2.3. Drugs 
D,L-cY-Difluoromethyl ornithine (DFMO) was 
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synthesized in our laboratories as in [3]. DFMO 
was administered in the drinking water as a 
2%-aqueous olution. The mean daily intake of the 
drug was found to be about 3 g.kg-‘.day. 
Putrescine was administered intraperitoneally at 
100 mg.kg-’ .day for 18 days. 
2.4. Polyamine analysis 
The tumor tissues were homogenized in 0.4 M 
perchloric acid, and the supernatants obtained 
after centrifugation were used for polyamine deter- 
mination by dansylation and subsequent thin-layer 
chromataography as in [lo]. 
3. RESULTS 
The effect of DFMO on the growth and 
polyamine content of Lewis lung tumor is 
presented in fig. 1. Administration of DFMO to 
animals bearing tumors resulted in a 69% and a 
75% decrease in the intracellular levels of 
putrescine and spermidine, respectively, without 
any change in the spermine concentrations. The 
decreased polyamine levels were also associated 
with an inhibition of tumor growth by 43%. In- 
hibition of polyamine biosynthesis as a result of 
DFMO administration not only inhibited growth 
of the primary tumor but also dramatically 
decreased the secondary pulmonary metastases by 
79% with 25% of the animals showing no visible 
metastases (table 1). Further, this inhibition of 
tumor growth and metastases could be reversed by 
simultaneous administration of putrescine to the 
animals (fig. 1 and table 1). Administration of 
putrescine to animals receiving DFMO did not 
result in any significant elevation of tumor 
putrescine concentration although spermidine con- 
centrations were substantially elevated compared 
to tumors from animals which received DFMO 
alone. The lack of any effect on tumor putrescine 
concentration following exogenous putrescine ad- 
ministration to DFMO-treated animals is most 
likely due to its rapid conversion to spermidine. 
Since polyamine depletion in tumor cells leads to 
an increase of S-adenosyl-L-methionine decarbox- 
ylase [7,12], the rate-limiting enzyme involved in 
the conversion of putrescine to spermidine, DFMO 
treatment is likely to facilitate the conversion of ex- 
ogenous putrescine to spermidine in the solid 
tumor employed here. 
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Fig. 1. Effect of DFMO on the growth and polyamine 
levels of Lewis lung tumor (3LL) in mice. Tumors were 
induced in C57 BL/6J mice by subcutaneous injection of 
1 x lo6 viable 3LL cells/mouse in the intrascapular 
region. DFMO was administered in the drinking water 
as a 2%-aqueous solution (-3 g. kg-‘.day-‘). Putre- 
seine was administered intraperitoneally at 
100 mg.kg-‘.day-‘. Points represent mean f SEM: 
(0) untreated animals; (0) DFMO-treated; (A) DFMO 
+ putrescine-treated animals. 
4. DISCUSSION 
The novel finding of this study is that inhibition 
of polyamine biosynthesis resulted in a decrease in 
the spread of the tumor cells to distant sites; i.e., 
metastases. The fact that the inhibition of 
metastases could be reversed by simultaneous ad- 
ministration of putrescine suggests that polyamines 
may play an important role not only in tumor 
growth [7,8] but also in the process of tumor 
metastases. Although the mechanism by which 
DFMO inhibits tumor metastases i  not yet clear, 
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Table 1 
Effect of DFMO on the inhibition of growth and pulmonary metastases of Lewis lung carcinoma in mice 
Treatment Tumor weight (g) (70 No. animals Metastatic foci 070 
(Mean f SE; n= 20) Inhibition showing no visible (Mean f SE; n = 20) Inhibition 
metastases 
Control 7.01 * 0.39 o/20 21.38 + 5.8 
DFMO 4.01 + 0.46b 43 5/20 4.60 f l.43b 79 
DFMO + Put. 6.54 f 0.72” 7 o/20 24.80 + 5.10a 0 
‘not significant; bsignificant at P < 0.01 
1 x lo6 3LL tumor cells/animal were injected subcutaneously at the intrascapular egion. DFMO was administered as 
2%-aqueous solution as the sole drinking fluid (-3 g/kg/day). Putrescine 100 mg/kg was given intraperitoneally daily, 
starting day l-18. At the end of 18 days the animals were killed, tumors were excised and weighed. Pulmonary 
metastases were determined as in [9] 
one can envisage that the depletion of cellular 
polyamines in the primary tumor could have 
affected: 
(i) The invasion of the tumor cells into the lym- 
phatics or blood vessels and their transport into 
distant organs; 
(ii) The establishment of a microenvironment un- 
favorable to the growth of pulmonary 
metastases [ 111. 
These results indicate that DFMO and other 
specific polyamine antimetabolites merit con- 
sideration as potential therapeutic agents in the 
clinical management of metastasis. 
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